drugset
drugset / Trial / NCT02981329

Fetal Hemoglobin Induction Treatment Metformin

NCT02981329 ↗

Phase 0 Completed 37 enrolled Baylor College of Medicine Pfizer · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether metformin is effective in the treatment for sickle cell anemia (SCA).

Timeline

Start
2017-03-02
Primary completion
2020-07-20
Completion
2020-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule — —

Indications

sickle cell disease